NCT03485508UnknownNot Applicable
Imaging and Risk Stratification in the Brugada Syndrome: a Follow-up Study
Universitair Ziekenhuis Brussel1 site in 1 country150 target enrollmentStarted: March 11, 2011Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Composed outcome of sudden cardiac death, appropriate ICD shock and witnessed ventricular fibrillation
Study Overview
Brief Summary
Although for many years the Brugada syndrome has been labelled as a purely electrical disease in the structurally normal heart, the evolution of imaging techniques has enabled the discovery of subtle morphofunctional alterations in some of the Brugada syndrome patients. We will use new echocardiographic techniques to assess cardiac function in these patients and new parameters will be evaluated for their prognostic value as risk stratificators.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •18 years or older
- •Diagnosis of Brugada syndrome
Exclusion Criteria
- •history of pericarditis, ischemic heart disease, cardiomyopathy of any origin, structural heart disease, or any other channelopathy
Outcomes
Primary Outcomes
Composed outcome of sudden cardiac death, appropriate ICD shock and witnessed ventricular fibrillation
Time Frame: 6 years
Sudden cardiac death is death occuring within 24 hours after being seen in a healthy status or within 1 hour after initiation of symptoms.
Secondary Outcomes
- Syncope(6 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Risk stratification in Brugada syndrome: analysis of unipolar Holter electrocardiogram after Pilsicainide provocation.Brugada syndromeJPRN-UMIN000035530Department of Medicine 2 Kansai Medical University50
Completed
Not Applicable
AnalyST & Brugada Syndrome - Feasibility StudyBrugada SyndromeNCT02052765Abbott Medical Devices16
Terminated
Phase 3
DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada SyndromeBrugada SyndromeNCT00701077Assistance Publique - Hôpitaux de Paris5
Unknown
Not Applicable
Rhythmic Risk of Type 1 Brugada Syndrome and Pulmonary Infundibulum MappingBrugada Syndrome Type 1NCT03572881Hospices Civils de Lyon10
Unknown
Not Applicable
Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective TrialBrugada SyndromeChannelopathiesVentricular FibrillationCardiac DeathNCT04580992Universitair Ziekenhuis Brussel25